The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment.

Marie-Pier  St-Laurent

Honoraria - Bayer; EMD Serono

Consulting or Advisory Role - Abbvie; Janssen

Bernhard  Eigl

Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; EMD Serono/Merck; Gilead Sciences; Janssen; Merck; Pfizer; Roche Canada; Seagen

Consulting or Advisory Role - EMD Serono; Gilead Sciences

Travel, Accommodations, Expenses - EMD Serono

Ren  Yuan

No Relationships to Disclose

Silvia  Chang

Honoraria - Bayer

Peter  Black

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Combat Medical; EMD Serono; Ferring; Janssen Oncology; Merck; Nanobot; Nanobot; NanOlogy; Nonagen Bioscience; Pfizer; Photocure; Prokarium; Sumitomo Pharma Oncology; TerSera; Tolmar; Verity Pharmaceuticals

Speakers' Bureau - Bayer; Janssen Oncology; Pfizer; TerSera

Patents, Royalties, Other Intellectual Property - 1. PCT/CA2014/000787. Canada. 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.